Return to Today's science sparks archives

2020-01-02

Figure 3. Etv6 binding precedes cohesin binding at cis-regulatory elements of genes upregulated during erythropoiesis.

Figure 3. Etv6 binding precedes cohesin binding at cis-regulatory elements of genes upregulated during erythropoiesis.
  • Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills R, Russell N, Osborne CS, Papaemmanuil E, Göttgens B, Campbell P, Huntly BJP

  • Blood. 2019 Dec 12;134(24):2195-2208.

2020-01-03

Fig. 3. The multi-step protocol used to provide a multianalyte gene expression assay result for GEP-NETs.

Fig. 3. The multi-step protocol used to provide a multianalyte gene expression assay result for GEP-NETs.
  • Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM

  • Adv Med Sci. 2019 Dec 13;65(1):18-29.

2020-01-06

Graphical Abstract

Graphical Abstract
  • Asciolla JJ, Resh MD

  • Cell Rep. 2019 Dec 24;29(13):4608-4619.e4.
Open Access button

2020-01-07

Fig 1. Patients classified by radiologically assessed response to immunotherapy.

Fig 1. Patients classified by radiologically assessed response to immunotherapy.
  • Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit DG, Ariyan CE

  • Ann Surg Oncol. 2019 Dec 17.

2020-01-08

Fig 2. Open in figure viewerPowerPoint
High‐grade endometrial stromal sarcoma (HGESS) harbouring BCOR internal tandem duplication (ITD).

Fig 2. Open in figure viewerPowerPoint High‐grade endometrial stromal sarcoma (HGESS) harbouring BCOR internal tandem duplication (ITD).
  • Momeni-Boroujeni A, Chiang S

  • Histopathology. 2020 Jan;76(1):64-75.
Open Access button

2020-01-09

Fig. 1: ENL mutations drive aberrant developmental programs and impair nephron differentiation.

Fig. 1: ENL mutations drive aberrant developmental programs and impair nephron differentiation.
  • Wan L, Chong S, Xuan F, Liang A, Cui X, Gates L, Carroll TS, Li Y, Feng L, Chen G, Wang SP, Ortiz MV, Daley SK, Wang X, Xuan H, Kentsis A, Muir TW, Roeder RG, Li H, Li W, Tjian R, Wen H, Allis CD

  • Nature. 2020 Jan;577(7788):121-126.

2020-01-10

Fig 2. MR images of a partial response (ongoing) achieved after 8 weeks of dabrafenib therapy in an 11-year-old male patient with BRAF V600–mutant ganglioglioma determined using coronal T1 postgadolinium contrast sequence.

Fig 2. MR images of a partial response (ongoing) achieved after 8 weeks of dabrafenib therapy in an 11-year-old male patient with BRAF V600–mutant ganglioglioma determined using coronal T1 postgadolinium contrast sequence.
  • Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, Geoerger B, Hingorani P, Dunkel IJ, Russo MW, Tseng L, Dasgupta K, Gasal E, Whitlock JA, Kieran MW

  • Clin Cancer Res. 2019 Dec 15;25(24):7303-7311.

2020-01-13

Figure 2. B7–H3 expression across WHO grade.

Figure 2. B7–H3 expression across WHO grade.
  • Maachani UB, Tosi U, Pisapia DJ, Mukherjee S, Marnell CS, Voronina J, Martinez D, Santi M, Dahmane N, Zhou Z, Hawkins C, Souweidane MM

  • Transl Oncol. 2019 Dec 27;13(2):365-371.
Open Access button

2020-01-14

Graphical Abstract.

Graphical Abstract.
  • Sanchez Bosch P, Makhijani K, Herboso L, Gold KS, Baginsky R, Woodcock KJ, Alexander B, Kukar K, Corcoran S, Jacobs T, Ouyang D, Wong C, Ramond EJV, Rhiner C, Moreno E, Lemaitre B, Geissmann F, Brückner K

  • Dev Cell. 2019 Dec 16;51(6):787-803.e5.

2020-01-15

Fig 2. AdnAB complex with forked duplex DNA.

Fig 2. AdnAB complex with forked duplex DNA.
  • Jia N, Unciuleac MC, Xue C, Greene EC, Patel DJ, Shuman S

  • Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24507-24516.
Open Access button

2020-01-16

Fig 3. Correlation heat map based on univariate linear regression analysis between each individual MR imaging phenotype and the recurrence predictor models of MammoPrint, Oncotype DX, PAM50 ROR-S, and PAM50 ROR-P.

Fig 3. Correlation heat map based on univariate linear regression analysis between each individual MR imaging phenotype and the recurrence predictor models of MammoPrint, Oncotype DX, PAM50 ROR-S, and PAM50 ROR-P.
  • Lo Gullo R, Daimiel I, Morris EA, Pinker K

  • Insights Imaging. 2020 Jan 3;11(1):1.
Open Access button

2020-01-17

Fig 3. Pathologic and genomic correlates of response.

Fig 3. Pathologic and genomic correlates of response.
  • Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, Capanu M, Zamarin D, Saltz LB, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, Reidy-Lagunes DL

  • J Clin Oncol. 2020 Jan 1;38(1):71-80.

2020-01-20

Fig 3. (A) Change in skin modified Severity Weighted Assessment Tool (mSWAT) scoring for patient 17 with transient skin flare reaction.

Fig 3. (A) Change in skin modified Severity Weighted Assessment Tool (mSWAT) scoring for patient 17 with transient skin flare reaction.
  • Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH.

  • J Clin Oncol. 2020 Jan 1;38(1):20-28.

2020-01-21

Graphical Abstract

Graphical Abstract
  • Granlund KL, Tee SS, Vargas HA, Lyashchenko SK, Reznik E, Fine S, Laudone V, Eastham JA, Touijer KA, Reuter VE, Gonen M, Sosa RE, Nicholson D, Guo YW, Chen AP, Tropp J, Robb F, Hricak H, Keshari KR

  • Cell Metab. 2020 Jan 7;31(1):105-114.

2020-01-22

Fig. 1 (a) Schematic of RStudio/shiny running on a server (“in the cloud”), immediately processing the user’s selections and rendering the new analysis in real time.

Fig. 1 (a) Schematic of RStudio/shiny running on a server (“in the cloud”), immediately processing the user’s selections and rendering the new analysis in real time.
  • Becker AS, Kirchner J, Sartoretti T, Ghafoor S, Woo S, Suh CH, Erinjeri JP, Hricak H, Vargas HA

  • J Digit Imaging. 2020 Jan 2;10.

2020-01-23

Fig. 1 Characterization of batch-produced microparticles with cell-like mechanical properties.

Fig. 1 Characterization of batch-produced microparticles with cell-like mechanical properties.
  • Vorselen D, Wang Y, de Jesus MM, Shah PK, Footer MJ, Huse M, Cai W, Theriot JA

  • Nat Commun. 2020 Jan 7;11(1):20.
Open Access button

2020-01-24

Graphical Abstract

Graphical Abstract
  • Maluski M, Ghosh A, Herbst J, Scholl V, Baumann R, Huehn J, Geffers R, Meyer J, Maul H, Eiz-Vesper B, Krueger A, Schambach A, van den Brink MR, Sauer MG

  • J Clin Invest. 2019 Dec 2;129(12):5108-5122.
Open Access button

2020-01-27

Figure 1. A, Epithelioid malignant mesothelioma shows malignant rounded epithelioid cells.

Figure 1. A, Epithelioid malignant mesothelioma shows malignant rounded epithelioid cells.
  • Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG 3rd, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Lang-Lazdunski L, Cree I, Rusch VW, Girard N, Galateau-Salle F

  • J Thorac Oncol. 2020 Jan;15(1):29-49.

2020-01-28

Figure 4. Existing classification systems are interconnected.

Figure 4. Existing classification systems are interconnected.
  • Dijk F, Veenstra VL, Soer EC, Dings MPG, Zhao L, Halfwerk JB, Hooijer GK, Damhofer H, Marzano M, Steins A, Waasdorp C, Busch OR, Besselink MG, Tol JA, Welling L, van Rijssen LB, Klompmaker S, Wilmink HW, van Laarhoven HW, Medema JP, Vermeulen L, van Hooff SR, Koster J, Verheij J, van de Vijver MJ, Wang X, Bijlsma MF

  • Sci Rep. 2020 Jan 15;10(1):337.
Open Access button

2020-01-29

Figure 6. Impact of 3′-terminal quadruplets on sequence selectivity of Rrp6p.

Figure 6. Impact of 3′-terminal quadruplets on sequence selectivity of Rrp6p.
  • Axhemi A, Wasmuth EV, Lima CD, Jankowsky E

  • Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):982-992.

2020-01-30

Fig.1. Conceptual Framework

Fig.1. Conceptual Framework
  • Fuzesi S, Becetti K, Klassen AF, Gemignani ML, Pusic AL

  • J Patient Rep Outcomes. 2019 Dec 27;3(1):73.
Open Access button

2020-01-31

Fig. 1: Best percent change in target lesions from baseline in MET-exon-14-altered NSCLCs.

Fig. 1: Best percent change in target lesions from baseline in MET-exon-14-altered NSCLCs.
  • Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, Murphy DA, Wang SC, Li S, Usari T, Wilner KD, Paik PK

  • Nat Med. 2020 Jan;26(1):47-51.

2020-02-03

Fig 2. Cumulative incidence of grades 3-5 cardiac outcomes among survivors of cancer in childhood by decade of cancer diagnosis and siblings.

Fig 2. Cumulative incidence of grades 3-5 cardiac outcomes among survivors of cancer in childhood by decade of cancer diagnosis and siblings.
  • Mulrooney DA, Hyun G, Ness KK, Ehrhardt MJ, Yasui Y, Duprez D, Howell RM, Leisenring WM, Constine LS, Tonorezos E, Gibson TM, Robison LL, Oeffinger KC, Hudson MM, Armstrong GT

  • BMJ. 2020 Jan 15;368:l6794.
Open Access button

2020-02-04

FIG 1. Sensitivity and specificity of human papillomavirus (HPV) types 16 and 33 droplet digital polymerase chain reaction (ddPCR) assays.

FIG 1. Sensitivity and specificity of human papillomavirus (HPV) types 16 and 33 droplet digital polymerase chain reaction (ddPCR) assays.
  • Damerla RR, Lee NY, You D, Soni R, Shah R, Reyngold M, Katabi N, Wu V, McBride SM1, Tsai CJ, Riaz N, Powell SN, Babady NE, Viale A, Higginson DS

  • JCO Precis Oncol. 2019;3:10.
Open Access button

2020-02-05

Figure 1. (A) The unique sampling geometry of golden‐angle radial sampling enables direct estimation of a temporal basis from the acquired data.

Figure 1. (A) The unique sampling geometry of golden‐angle radial sampling enables direct estimation of a temporal basis from the acquired data.
  • Feng L, Wen Q, Huang C, Tong A, Liu F, Chandarana H

  • Magn Reson Med. 2020 Jan;83(1):94-108.

2020-02-06

Fig. 1. Block diagram for CS and ROICS reconstruction based on reconstruction type selection and its results at the chosen acceleration factor for demonstrating its utility.

Fig. 1. Block diagram for CS and ROICS reconstruction based on reconstruction type selection and its results at the chosen acceleration factor for demonstrating its utility.
  • Konar AS, Vajuvalli NN, Rao R, Jain D, Ramesh Babu DR, Geethanath S

  • Magn Reson Imaging. 2019 Nov 18;67:18-23.

2020-02-07

Figure 1. Representative H&E, PD-L1 IHC, and CD8+ T-cell IHC of baseline colon tumor specimens of patients treated with pembrolizumab (anti–PD-1).

Figure 1. Representative H&E, PD-L1 IHC, and CD8+ T-cell IHC of baseline colon tumor specimens of patients treated with pembrolizumab (anti–PD-1).
  • Llosa NJ, Luber B, Siegel N, Awan AH, Oke T, Zhu Q, Bartlett BR, Aulakh LK, Thompson ED, Jaffee EM, Durham JN, Sears CL, Le DT, Diaz LA Jr, Pardoll DM, Wang H, Housseau F, Anders RA

  • Cancer Immunol Res. 2019 Oct;7(10):1574-1579.
Open Access button

2020-02-11

Table 1: Comfort level before and after mock drill.

Table 1: Comfort level before and after mock drill.
  • LeBoeuf J, Pritchett W

  • Clin J Oncol Nurs. 2020 Feb 1;24(1):E7-E12.

2020-02-12

Fig. 2. A-F. Trends in Death at Home or Hospice (1999–2017 aggregate data).

Fig. 2. A-F. Trends in Death at Home or Hospice (1999–2017 aggregate data).
  • Stephens SJ, Chino F, Williamson H, Niedzwiecki D, Chino J, Mowery YM

  • Oral Oncol. 2020 Jan 29;102:104555.

2020-02-13

FIGURE 1. Functional overlap of acute myeloid leukemia driver mutations.

FIGURE 1. Functional overlap of acute myeloid leukemia driver mutations.
  • Kishtagari A, Levine RL, Viny AD

  • Curr Opin Hematol. 2020 Mar;27(2):49-57.

2020-02-14

Fig 1. Individual responses by tumour type

Fig 1. Individual responses by tumour type
  • Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators

  • Lancet Oncol. 2020 Feb;21(2):271-282.

2020-02-17

Fig 1. Transcriptional analysis of tumour specimens from patients with high-risk resectable melanoma and metastatic RCC treated with pre-surgical ICB

Fig 1. Transcriptional analysis of tumour specimens from patients with high-risk resectable melanoma and metastatic RCC treated with pre-surgical ICB
  • Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R4, Woodman S11, Keung EZ6, Gaudreau PO6, Reuben A13, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA

  • Nature. 2020 Jan;577(7791):549-555.

2020-02-18

Central Illustration. Global Longitudinal Strain in Immune Checkpoint Inhibitor-Myocarditis

Central Illustration. Global Longitudinal Strain in Immune Checkpoint Inhibitor-Myocarditis
  • Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, Murphy SP, Mercaldo ND, Zhang L, Zlotoff DA, Reynolds KL, Alvi RM, Banerji D, Liu S, Heinzerling LM, Jones-O'Connor M, Bakar RB, Cohen JV, Kirchberger MC, Sullivan RJ, Gupta D, Mulligan CP, Shah SP, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Lawrence DP, Mahmoudi M, Devereux RB, Forrestal BJ, Mandawat A, Lyon AR, Chen CL, Barac A, Hung J, Thavendiranathan P, Picard MH, Thuny F, Ederhy S, Fradley MG, Neilan TG

  • J Am Coll Cardiol. 2020;75(5):467-78.

2020-02-19

Fig 8. Energy spectra from PIV at LDA crossing for different optical turbulence strengths are consistent with spectra calculated from corresponding LDA data.

Fig 8. Energy spectra from PIV at LDA crossing for different optical turbulence strengths are consistent with spectra calculated from corresponding LDA data.
  • Matt S, Nootz G, Hellman S, Hou W

  • Sci Rep. 2020 Feb 7;10(1):2130.
Open Access button

2020-02-20

Fig 1. The Challenge of Optimizing FMT.

Fig 1. The Challenge of Optimizing FMT.
  • Markey KA, van den Brink MRM, Peled JU

  • Cell Host Microbe. 2020 Feb 12;27(2):169-172.

2020-02-21

Fig 1. Ars2 is required for embryonic NSC development.

Fig 1. Ars2 is required for embryonic NSC development.
  • Yu Y, Andreu-Agullo C, Liu BF, Barboza L, Toth M, Lai EC

  • Development. 2020 Jan 22;147(2). pii: dev180018.
Open Access button

2020-02-24

Fig 1. Genomic alterations in sRCCs by targeted panel sequencing

Fig 1. Genomic alterations in sRCCs by targeted panel sequencing
  • Malouf G, Flippot R, Dong Y, Dinatale RG, Chen YB, Su X, Compérat E, Rouprêt M, Mano R, Blum KA, Yao H, Mouawad R, Spano JP, Khayat D, Karam JA, Ho TH, Tickoo SK, Russo P, Hsieh JJ, Tannir NM, Hakimi AA

  • Sci Rep. 2020 Jan 20;10(1):701.
Open Access button

2020-02-25

Fig. 4. Immune phenotype of KRAS co-mutated subgroups.

Fig. 4. Immune phenotype of KRAS co-mutated subgroups.
  • Friedlaender A, Drilon A, Weiss GJ, Banna GL, Addeo A

  • Cancer Treat Rev. 2020 Feb 7;85:101978.

2020-02-26

Fig 6. Advective flux vectors along the MCA show aberrant flow in SHRSP.

Fig 6. Advective flux vectors along the MCA show aberrant flow in SHRSP.
  • Kounda S, Elkin R, Nadeem S, Xue Y, Constantinou S, Sanggaard S, Liu X, Monte B, Xu F, Van Nostrand W, Nedergaard M, Lee H, Wardlaw J, Benveniste H, Tannenbaum A

  • Sci Rep. 2020 Feb 6;10(1):1990.
Open Access button

2020-02-27

Fig 5. FLARE in PML-RARα transgenic mouse model.

Fig 5. FLARE in PML-RARα transgenic mouse model.
  • Qi Y, Fang Y, Sinclair DR, Guo S, Alberich-Jorda M, Lu J, Tenen DG, Kharas MG, Pyne S

  • PLoS One. 2020 Feb 11;15(2):e0228651.
Open Access button

2020-02-28

Figure 1.Three-dimensional waterfall and swim plots of arm A (A), arm B (B), arm C (C), arm D (D), and arm E (E).

Figure 1.Three-dimensional waterfall and swim plots of arm A (A), arm B (B), arm C (C), arm D (D), and arm E (E).
  • Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY

  • Clin Cancer Res. 2020 Feb 15;26(4):846-854.

2020-03-02

Fig. 1: Clinical presentation and genetic features of patients with iMCD-TAFRO.

Fig. 1: Clinical presentation and genetic features of patients with iMCD-TAFRO.
  • Yoshimi A, Trippett TM, Zhang N, Chen X, Penson AV, Arcila ME, Pichardo J, Baik J, Sigler A, Harada H, Fajgenbaum DC, Dogan A, Abdel-Wahab O, Xiao W

  • Oncogene. 2020 Feb 12:10.1038/s41388-020-1204-9.

2020-03-03

Figure 1. Planned intensity and duration of each individual session (ie, dose) and schedule of treatment dose across the study intervention period for linear dosing and nonlinear dosing.

Figure 1. Planned intensity and duration of each individual session (ie, dose) and schedule of treatment dose across the study intervention period for linear dosing and nonlinear dosing.
  • Scott JM, Thomas SM, Peppercorn JM, Herndon JE, Douglas PS, Khouri MG, Dang CT, Yu AF, Catalina D, Ciolino C, Capaci C, Michalski MG, Eves ND, Jones LW

  • Circulation. 2020 Feb 18;141(7):560-570

2020-03-04

Fig 1. Relative rank ordering of freelisting items (n = 65).

Fig 1. Relative rank ordering of freelisting items (n = 65).
  • Meghani SH, Wool J, Davis J, Yeager KA, Mao JJ, Barg FK

  • J Pain Symptom Manage. 2020 Mar;59(3):618-625.

2020-03-06

Fig 3. Schematic of skin surface co-registration.

Fig 3. Schematic of skin surface co-registration.
  • Stember JN, Terilli KL, Perez E, Megjhani M, Cooper CA, Jambawalikar S, Park S

  • J Digit Imaging. 2020 Feb 19.

2020-03-09

Graphical Abstract.

Graphical Abstract.
  • Duan ZRS, Che A, Chu P, Modol L, Bollmann Y, Babij R, Fetcho RN, Otsuka T, Fuccillo MV, Liston C, Pisapia DJ, Cossart R, De Marco García NV

  • Neuron. 2020 Jan 8;105(1):75-92.e5.

2020-03-10

Figure 1: Genomic alterations in sRCCs by targeted panel sequencing.

Figure 1: Genomic alterations in sRCCs by targeted panel sequencing.
  • Malouf GG, Flippot R, Dong Y, Dinatale RG, Chen YB, Su X, Compérat E, Rouprêt M, Mano R, Blum KA, Yao H7, Mouawad R, Spano JP, Khayat D, Karam JA, Ho TH, Tickoo SK, Russo P, Hsieh JJ, Tannir NM, Hakimi AA

  • Sci Rep. 2020 Jan 20;10(1):701.
Open Access button

2020-03-11

Graphical Abstract.

Graphical Abstract.
  • Laks E, McPherson A, Zahn H, Lai D, Steif A, Brimhall J, Biele J, Wang B, Masud T, Ting J, Grewal D, Nielsen C...CRUK IMAXT Grand Challenge Team, Marra MA, Hansen C, Shah SP, et al.

  • Cell. 2019 Nov 14;179(5):1207-1221.e22.
Open Access button

2020-03-12

Fig. 1. Study design. LAN–PRRT, lanreotide autogel/depot combined with peptide receptor radionuclide therapy.

Fig. 1. Study design. LAN–PRRT, lanreotide autogel/depot combined with peptide receptor radionuclide therapy.
  • Prasad V, Srirajaskanthan R, Toumpanakis C, Grana CM, Baldari S, Shah T, Lamarca A, Courbon F, Scheidhauer K, Baudin E, Truong Thanh XM, Houchard A, Dromain C, Bodei L

  • Eur J Nucl Med Mol Imaging. 2020 Feb 15.

2020-03-13

Fig. 4: CD36 deficiency stimulates apoptosis in intratumoral Treg cells.

Fig. 4: CD36 deficiency stimulates apoptosis in intratumoral Treg cells.
  • Wang H, Franco F, Tsui YC, Xie X, Trefny MP, Zappasodi R, Mohmood SR, Fernández-García J, Tsai CH, Schulze I, Picard F, Meylan E, Silverstein R, Goldberg I, Fendt SM, Wolchok JD, Merghoub T, Jandus C, Zippelius A, Ho PC

  • Nat Immunol. 2020 Mar;21(3):298-308.

2020-03-16

Fig. 4: Monocytes do not persist in the peri-infarct area.

Fig. 4: Monocytes do not persist in the peri-infarct area.
  • Werner Y, Mass E, Ashok Kumar P, Ulas T, Händler K, Horne A, Klee K, Lupp A, Schütz D, Saaber F, Redecker C, Schultze JL, Geissmann F, Stumm R

  • Nat Neurosci. 2020 Feb 10:10.1038/s41593-020-0585-y.

2020-03-18

Figure 2: Mathematical modeling predicts optimal treatment schedule.

Figure 2: Mathematical modeling predicts optimal treatment schedule.
  • Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L

  • Haematologica, 105 (3), e91-e94.
Open Access button

2020-03-19

Figure 1. MRI imaging

Figure 1. MRI imaging
  • de la Fuente MI, Rosenblum MK, Diamond EL, Tabar VS, Omuro A

  • Neurol Neuroimmunol Neuroinflamm. 2020 Mar 2;7(3):e686.
Open Access button

2020-03-20

Fig. 1. Synthesis and size characterization of fluorescent protein nanoparticles.

Fig. 1. Synthesis and size characterization of fluorescent protein nanoparticles.
  • An F, Chen N, Conlon WJ, Hachey JS, Xin J, Aras O, Rodriguez EA, Ting R

  • Int J Biol Macromol. 2020 Feb 24;153:100-106.

2020-03-23

Fig 1. Estimated absolute risk of developing breast cancer for women with germline PALB2 pathogenic variants (PVs) by age

Fig 1. Estimated absolute risk of developing breast cancer for women with germline PALB2 pathogenic variants (PVs) by age
  • Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM.... Tischkowitz M

  • J Clin Oncol. 2020 Mar 1;38(7):674-685.

2020-03-24

Table 2. Results of the 2 rounds of rating.

Table 2. Results of the 2 rounds of rating.
  • Cohen R,Vernerey D,Bellera C,Meurisse A,Henriques J,Paoletti X,Rousseau B,Alberts S,Aparicio T,Boukovinas I,Gill S,Goldberg RM,Grothey A,Hamaguchi T,Iveson T,Kerr R,Labianca R,Lonardi S,Meyerhardt J,Paul J,Punt CJA,Saltz L,Saunders MP,Schmoll HJ,Shah M,Sobrero A,Souglakos I,Taieb J,Takashima A,Wagner AD,Ychou M,Bonnetain F,Gourgou S,Yoshino T,Yothers G,de Gramont A,Shi Q,Andre T

  • Eur J Cancer. 2020 Mar 12;130:63-71.

2020-03-25

Fig 3. Bone marrow aspirate smears from patients with chromothripsis-negative AML-MRC revealed a typical myeloid blast morphology (Giemsa, ×1000).

Fig 3. Bone marrow aspirate smears from patients with chromothripsis-negative AML-MRC revealed a typical myeloid blast morphology (Giemsa, ×1000).
  • Gao J, Chen YH, Mina A, Altman JK, Kim KY, Zhang Y, Lu X, Jennings L, Sukhanova M

  • Hum Pathol. 2020 Feb 21;98:22-31.

2020-03-26

Fig 7. Model of oncogenic splicing factor mutation-induced altered splicing and aberrant NMD.

Fig 7. Model of oncogenic splicing factor mutation-induced altered splicing and aberrant NMD.
  • Rahman MA,Lin KT,Bradley RK,Abdel-Wahab O,Krainer AR

  • Genes Dev. 2020 Mar 1;34(5-6):413-427.

2020-03-27

Fig 1. All-cause cumulative mortality more than 5 years from cancer diagnosis for cancer survivors

Fig 1. All-cause cumulative mortality more than 5 years from cancer diagnosis for cancer survivors
  • Suh E, Stratton KL, Leisenring WM, Nathan PC, Ford JS, Freyer DR, McNeer JL, Stock W, Stovall M, Krull KR, Sklar CA, Neglia JP, Armstrong GT, Oeffinger KC, Robison LL, Henderson TO

  • Lancet Oncol. 2020 Mar;21(3):421-435.

2020-03-30

Fig 3. DFS (A) and OS (B) for the entire cohort stratified by TMB using a binary cutoff of 2.8 (third quartile). OS by TMB in patients with fusion-negative RMS (C); fusion-positive RMS (D); localized RMS (low/intermediate risk; E); and metastatic RMS (high risk; F).

Fig 3. DFS (A) and OS (B) for the entire cohort stratified by TMB using a binary cutoff of 2.8 (third quartile). OS by TMB in patients with fusion-negative RMS (C); fusion-positive RMS (D); localized RMS (low/intermediate risk; E); and metastatic RMS (high risk; F).
  • Casey DL, Wexler LH, Pitter KL, Samstein RM, Slotkin EK, Wolden SL

  • Clin Cancer Res. 2020 Mar 1;26(5):1135-1140.

2020-03-31

Figure 1. Brief summary of key clinical trials for programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) blockade.

Figure 1. Brief summary of key clinical trials for programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) blockade.
  • Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Travis W, Yoshida A, Daigneault JB, Wistuba II, Mino-Kenudson M

  • J Thorac Oncol. 2020 Apr;15(4):499-519. doi: 10.1016/j.jtho.2019.12.107. Epub 2019 Dec 20.
Open Access button

2020-04-01

Abstract. Clearing agents (CAs) can rapidly remove nonlocalized targeting biomolecules from circulation for hepatic catabolism, thereby enhancing the therapeutic index (TI), especially for blood (marrow), of the subsequently administered radioisotope in any multistep pretargeting strategy.

Abstract. Clearing agents (CAs) can rapidly remove nonlocalized targeting biomolecules from circulation for hepatic catabolism, thereby enhancing the therapeutic index (TI), especially for blood (marrow), of the subsequently administered radioisotope in any multistep pretargeting strategy.
  • Cheal SM, Patel M, Yang G, Veach D, Xu H, Guo HF, Zanzonico PB, Axworthy DB, Cheung NV, Ouerfelli O, Larson SM

  • Bioconjug Chem. 2020 Mar 18;31(3):501-506. doi: 10.1021/acs.bioconjchem.9b00736. Epub 2020 Feb 10.